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Abstract 
cis-Diamminedichloroplatinum (cisplatin) is widely accepted as 
chemotherapeutic drugs. However, the initial trial of cisplatin causes severe side 
effects in normal tissues, including neurotoxicity, ototoxicity, nephrotoxicity and so 
on. Among these side effects, nephrotoxicity remains a major factor that limits the 
use of cisplatin in cancer therapy. Cisplatin-induced nephrotoxicity is mediated by 
generation ofreactive oxygen species (ROS) in renal tubular cells. Cyanidin belongs 
to anthocyanin, which distributes widely in food diet. However, the protective effects 
of cyanidin on proximal tubular cells against cisplatin are still unknown. Therefore, 
the objective ofthis study was to investigate in vitro protective effects ofcyanidin on 
cisplatin-induced apoptotic cell death and the underlying mechanisms. 
Our results showed that cisplatin inhibited the growth ofproximal tubular HK-2 
cells through induction of apoptosis，as evidenced by chromatin condensation and 
DNA fragmentation. Interestingly, cisplatin-induced apoptosis was significantly 
attenuated by co-incubation with cyanidin. We also showed that activation ofcaspase 
and cleavage of poly (ADP-ribose) polymerase (PARP) in cisplatin-treated cells 
could be effectively blocked by cyanidin. Moreover, cyanidin prevented the 
cisplatin-induced loss of mitochondrial membrane potential (A^Fm) by regulating the 
expression and phosphorylation ofBcl-2 family members, including the pro-survival 
and pro-apoptotic proteins. HK-2 cells exposed to cisplatin showed increase in total 
and phosphorylated p53 on serine residues of Ser 392, Ser 15 and Ser 9. However, 
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cyanidin demonstrated the ability to suppress cisplatin-induced total and 
phosphorylated p53 activation. Furthermore, cyanidin prevented the 
cisplatin-induced overproduction of intracellular ROS and subsequent DNA damage. 
Additionally, cisplatin treatment triggered the activation ofmitogen-activated protein 
kinases (MAPKs) and AKT pathways, which were also effectively suppressed by 
cyanidin. Inhibitors o fERK (U0126) or AKT (LY294002), but not JNK (SP600125) 
and p38 MAPK (SB203580), significantly suppressed cisplatin-induced apoptosis in 
HK-2 cells. Taken together, our results suggest that cyanidin protects HK-2 cells 
against cisplatin-induced apoptosis through inhibiting the ROS generation and 























P T C Proximal tubular cell 
R O S Reactive oxygen species 
D S B s DNA strand breaks 
J C " 1 4',6-Diamidino-2-phenyindole 
DCF-DA 2',7'-dichlorofluorescein diacetate 
D A P I 4',6-Diamidino-2-phenyindole 
E R Endoplasmic Reticulum 
顶 1 7 , Tumor-necrosis factor-a 
™ F R Tumor-necrosis factor-a receptor 
C Y P Cytochrome P450 
A ^ m Mitochondrial membrane potential 
PI Propidium iodide 
LDH Lactate dehydrogenase 
M T T 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
E D T A Ethylenediaminetetraacetic acid 
DMEM Dulbecco's modified Eagle's medium 
D M S 0 Dimethylsulfoxide 
PBS Phosphate buffered saline 
I C 5 0 Halfmaximal inhibitory concentration 
V 
PUMA-a p53-upregulated modulator of apoptosis 
MAPK Mitogen-activated protein kinase 
ERK Extracellular-regulated kinase 
JNK c-Jun NH2-terminal kinase 
SAPK Stress-activated protein kinase 
PARP Poly (ADP-Ribose) Polymerase 
FBS Fetal bovine serum 
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Chapter One: Introduction 
1.1. Cancer 
Cancer, with medical term of malignartt neoplasm, is a class of diseases in 
which the cells with characteristics of uncontrolled growth, invasion, and sometimes 
metastasis. "Uncontrolled growth" means spreading to other locations in the body via 
lymph or blood, "invasion" is shown as growth and division beyond the normal 
limits, while "metastasis" evidences as intrusion on and destruction of adjacent 
tissues. These three malignant properties of cancers differentiate from those of 
benign tumors, which are self-limited, and do not invade or metastasize. Cancer may 
affect people at all ages and the risk increases with age. It is becoming a growing 
health problem around the world with causing about 13 % of all human deaths. 
According to a recent report by the American Cancer Society, cancer causes over 10 
% of overall deaths. During 2007, 7.6 million people died from cancer in the world. 
Over the past 30 years, the incidence of some tumors decreased while that of others 
increased. For example, the incidence of stomach cancer has decreased about 63 % 
since 1947. 
Cancer development is a long-time process and caused by abnormalities in the 
genetic material of transformed cells. These abnormalities may be due to the effects 
of carcinogens, such as radiation, chemicals, or infectious agents. The 
carcinogenesis events go forward and finally result in spreading of cancer cells from 
one area to other parts of a body during the metastasis stage. 
Definitive diagnosis of cancer requires histologic examination on a biopsy 
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specimen. Most cancers can be treated and some forced into remission, depending on 
the specific type, stage and location. Cancers are classified by the tissue presumed to 
be the origin of the tumor. Examples of general categories include carcinoma, 
sarcoma, lymphoma, germ cell tumor and blastoma. Carcinoma is a type of 
malignant tumors derived from epithelial cells, which represents the most common 
cancers, including breast, prostate, lung and colon cancer. Sarcoma is a type of 
malignant tumors derived from connective tissues, or mesenchymal cells, while 
lymphoma, also known as leukemia, is derived from hematopoietic (blood-forming) 
cells. Germ cell tumor is derived from totipotent cells. Blastoma, also known as 
blastic tumor, is a tumor (usually malignant) which resembles an immature or 
embryonic tissue, which is commonly found in children. 
At present, cancer can be treated by surgery, chemotherapy, radiation therapy, 
immunotherapy, or the combination of them. The choice of therapy is depending on 
the location and grade of the tumor, the stage of the disease, as well as the general 
state of the patient. Among these treatments, chemotherapy is one of the most 
commonly adopted treatments in a cancer therapy. 
1.2. Chemotherapy 
Chemotherapy is the treatment of disease by chemicals, especially by killing 
micro-organisms or cancerous cells. The first modern chemotherapeutic agent was 
Paul Ehrlich's arsphenamine, an arsenic compound discovered in 1909 designed to 
treat syphilis. Then, penicillin was discovered by Alexander Fleming while Domagk 
discovered sulfonamides afterwards. 
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Most commonly, chemotherapy acts by killing cells that divide rapidly, one of 
the main properties of cancer cells. This means that it also harms normal cells that 
divide rapidly. These include the cells in the bone marrow, digestive tract and hair 
follicles, which results in the most common side effects of 
chemotherapy一myelosuppression (decreased production of blood cells), mucositis 
(inflammation of the lining of the digestive tract) and alopecia (hair loss). 
In the broad sense, most chemotherapeutic drugs work by impairing mitosis 
(cell division), effectively targeting fast-dividing cells. Some drugs cause cells to 
undergo apoptosis. 
1.3. Cisplatin 
Cisplatin is widely used for chemotherapy and is potent for various types of 
solid tumors, including ovarian, testicular, head and neck and uterine cervical 
carcinoma (Osanto et al., 1992). Cisplatin was discovered over four decades ago and 
demonstrated one of the highest cure rates, for instance, over 90 % in testicular 
cancers (Arany and Safirstein, 2003, Cohen and Lippard, 2001, Siddik, 2003, Wang 
and Lippard, 2005). 
Unlike most chemotherapeutic drugs, which are usually complex organic 
compounds, cisplatin is a simple organic molecule. Although the mechanism of the 
anticancer effects of cisplatin is not completely understood, some hold the view that 
cisplatin binds to DNA, leading to the formation of inter- and intrastrand cross-links 
(Ciccarelli et al., 1985, Eastman, 1987, Heiger-Bernays et aL, 1990, Jamieson and 
Lippard, 1999, Wang and Lippard, 2005, Zamble and Lippard, 1995). Cross-linking 
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results in defective DNA templates and arrest of DNA synthesis and replication. In 
rapidly dividing cells, which are the symbols of cancer cells, cross-linking can 
further induce DNA damage. Extensive DNA damage leads to irreversible injury and 
cell death. 
Although cisplatin has been a miracle for cancer therapy, it has two major 
limiting factors: acquired resistance to cisplatin and severe side effects in normal 
tissues (Siddik, 2003, Wang and Lippard, 2005). The side effects of cisplatin usage 
include neurotoxicity, ototoxicity, nausea, vomiting and nephrotoxicity. For years, 
various approaches have been attempted to curtail these side effects. Among these 
side effects of cisplatin, nephrotoxicity remains a major factor that limits the use and 
efficacy of cisplatin in cancer therapy. 
1.4. Cisplatin-induced nephrotoxicity 
Cisplatin induces a frequent adverse effect in renal tubules and leads to acute 
renal failure. Nephrotoxicity was reported in the initial clinical trials of cisplatin 
chemotherapy (Hill and Speer, 1982). The prevalence of cisplatin nephrotoxicity is 
high and about one-third of patient suffered from it during treatment (Luke et al., 
1992). Clinically, cisplatin-induced nephrotoxicity is often seen after 10 days of 
cisplatin administration and is manifested as lower glomerular filtration rate, higher 
serum creatinine and reduced serum magnesium and potassium levels (Arany and 
Safirstein, 2003, Gomez Campdera et al., 1986, Gonzales-Vitale et al., 1977). 
Cisplatin-induced nephrotoxicity is recognized as a very complex multifactorial 
process. The pathophysiological basis of cisplatin nephrotoxicity was studied during 
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for the last three decades. However, only recent researches directed towards the 
understandings of the cellular and molecular mechanisms. Primary targets of 
cisplatin in kidney are proximal tubules, where it promotes cellular damage, and 
induces nephrotoxicity through oxidative stress, DNA damage, cell apoptosis, and 
inflammation (Ramesh and Reeves, 2002, Winston and Safirstein, 1985). 
1.5. Mechanisms of cisplatin-induced nephrotoxicity 
Renal tissue damage, characterized by tubular cell death, is a common 
histopathological feature of cisplatin nephrotoxicity. Under this condition, cell death 
in the forms of both necrosis and apoptosis is identified. Further investigation about 
the cell types that undergo apoptosis during cisplatin-induced nephrotoxicity have 
been carried out. The observations showed that apoptosis occurs in both tubular 
segments, but majority in proximal tubules. 
1.5.1. Apoptosis in cisplatin-induced nephrotoxicity 
Apoptosis is the process of programmed cell death that occurs in multicellular 
organisms. It leads to changes in cell morphology and death. These changes include 
loss of cell membrane asymmetry and attachment, blebbing, cell shrinkage, nuclear 
and chromosomal DNA fragmentation and chromatin condensation. Apoptosis differs 
from necrosis, in which the cellular debris can damage the organism. Apoptosis 
confers advantages during an organism's life cycle. About 50 to 70 billion cells die 
every day due to apoptosis in an average human adult. In average, in the body of a 
child between the ages of 8 and 14, approximately 20 billion to 30 billion cells die 
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per day. The number of research on apoptosis has been substantially increased since 
the early 1990s. In addition to its importance as a biological phenomenon, a defective 
apoptotic process leads to an extensive variety of diseases. Excessive apoptosis 
causes atrophy, such as in ischemic damage, whereas an insufficient amount results 
in uncontrolled cell proliferation, such as cancer. 
During the last few years, apoptosis of renal tubular cells became the focus of 
mechanistic investigation of cisplatin-induced nephrotoxicity. Several apoptotic 
pathways were involved, including the extrinsic pathway mediated by death 
receptors, the intrinsic pathway centered on mitochondria and the endoplasmic 
reticulum (ER)-stress pathway (Danial and Korsmeyer’ 2004, Green and Reed, 1998, 
Pabla and Dong, 2008, Strasser et al., 2000). In the extrinsic pathway, binding of the 
death receptors by ligands at the plasma membrane leads to the activation of 
caspase-8, which further induces apoptosis (Strasser et aL, 2000). Major death 
receptors include Fas, tumor-necrosis factor-a (TNF-a) receptor (TNFR) 1 and 2. For 
example, an upregulation of Fas and Fas ligand by cisplatin, which was associated 
with apoptosis, was shown in cultured human proximal tubular cells (Razzaque et al., 
1999). The intrinsic (mitochondrial) pathway has emerged as the major apoptotic 
pathway in cisplatin-induced nephrotoxicity. In the intrinsic pathway, cellular stress 
leads to the activation of Bcl-2 family proteins, which forms porous defects on the 
outer membrane of mitochondria, resulting in the release of apoptogenic factors from 
the organelles and leads to the activation of caspase-9, which also induces apoptosis 
(Danial and Korsmeyer, 2004, Green and Reed, 1998, Strasser et al., 2000). In 
addition to the extrinsic and intrinsic pathways, tubular cell apoptosis following 
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cisplatin treatment may also involve the ER-stress pathway. ER stress activates 
caspase-12, which localizes at the cytosolic face of ER, and leads to apoptosis 
(Boyce and Yuan, 2006). Recent study showed that caspase-12 was activated during 
cisplatin treatment of LLC-PK1 cells and transfection of anti-caspase-12 antibody 
attenuated apoptosis (Liu and Baliga, 2005). The in vitro observations on a rat model 
of cisplatin-induced nephrotoxicity, ER stress and related signaling such as 
caspase-12 cleavage were demonstrated (Peyrou et aL, 2007). 
1.5.2. MAPK activation in cisplatin-induced nephrotoxicity 
Mitogen-activated protein kinases (MAPKs) are serine/threonine kinases. The 
MAPK-signaling pathways result in terminal activation of ERK (extracellular 
signal-regulated kinase), p38 and JNK (Jun N-terminal kinase) or SAPK 
(stress-activated protein kinase) (Dhillon et al., 2007, Owens and Keyse, 2007). They 
can regulate various cellular responses, including cell proliferation, differentiation 
and apoptosis (Cross et al., 2000). ERK, p38, and JNK/SAPK are activated in 
various experimental models of cisplatin-induced nephrotoxicity. However, the roles 
played by specific MAPKs in cisplatin-induced renal injury are very complicated, 
varying between different studies, and depending on the cell types and experimental 
models and conditions to be examined. In in vivo studies, cisplatin induced the 
activation of ERK, p38, and JNK/SAPK, which preceded the development of acute 
renal injury and renal failure (Arany et al., 2004). The role for ERK activation in 
cisplatin-induced nephrotoxicity in vivo was recently verified by using U0126 (Jo et 
al.，2005), which is a specific ERK inhibitor. Meanwhile, a study of the treatment 
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with the JNK inhibitor SP600125 showed reduction of renal apoptosis and 
inflammation during cisplatin-induced nephrotoxicity using an in vivo rat model 
(Francescato et al.，2007). ERK and JNK usually directly regulate renal tubular cell 
apoptosis. However, instead of directly regulating tubular cell death, p38 may 
regulate TNF-a expression and consequent inflammatory response during 
cisplatin-induced nephrotoxicity (Mishima et al., 2006, Ramesh and Reeves, 2005). 
1.5.3. Oxidative stress in cisplatin-induced nephrotoxicity 
Oxidative stress represents an imbalance between the production of reactive 
oxygen species and detoxification of the reactive intermediates. Disturbances in the 
normal redox state of tissues can cause toxic effects through the production of 
peroxides and free radicals that damage all components of the cell, including proteins, 
lipids, and DNA. In humans, oxidative stress is involved in many diseases, 
including Parkinson's disease, heart failure, myocardial infarction, Alzheimer's 
disease and chronic fatigue syndrome (de Diego-Otero et al.，2009). 
Over a decade, oxidative stress has been recognized as an important factor that 
contributes to cisplatin-induced nephrotoxicity (Baliga et al., 1999). The increment 
of various reactive oxygen species (ROS) has been demonstrated to occur during 
cisplatin treatment of cultured renal tubular cells, kidney slices, and in vivo in whole 
animals. Three mechanisms have been proposed to account for ROS generation with 
cisplatin treatment. First, cisplatin shifts to a highly reactive form in the cells and 
rapidly reacts with thiol-containing molecules including glutathinone, a 
well-recognized cellular antioxidant (Arany and Safirstein, 2003, Siddik，2003). 
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Depletion of glutathione and related antioxidants is expected to shift the cellular 
redox status, leading to the accumulation of endogenous ROS within the cells. 
Second, cisplatin may induce mitochondrial dysfunction and increase ROS 
production via the disrupted respiratory chain. For example, cisplatin treatment for 
20 min reduced the activity of mitochondrial respiration complexes I-IV, resulting in 
ROS generation in porcine proximal tubular cells (Kruidering et aL, 1997). Finally, 
cisplatin may induce ROS formation in the microsomes via the cytochrome P450 
(CYP) system. Using both in vitro and in vivo models, the results showed that CYP 
was an important source of catalytic iron for ROS generation during cisplatin 
treatment (Baliga et al., 1999, Baliga et aL, 1998b, Baliga et al.，1998a, Liu and 
Baliga, 2003). In CYP2El-null mice, the accumulation of ROS induced by cisplatin 
was attenuated, so was renal injury (Liu and Baliga, 2003). 
The central role of ROS accumulation in cisplatin-induced renal failure (Davis 
et al., 2001) is also supported by studies that demonstrate a protective role for ROS, 
such as catalase, vitamin E and glutathione, in cisplatin-mediated nephrotoxicity 
(Appenroth et aL, 1997, Lieberthal et al., 1996, McGinness et al., 1978, 
Tsutsumishita et al., 1998) For example, another study conducted in 1999 showed 
that oral supplementation of vitamin E could effectively decrease the incidence and 
severity of cisplatin-induced peripheral neurotoxicity and nephrotoxicity (Pace et al., 
2003). O f note, in addition to the tested chemicals，antioxidant agents extracted from 
natural products have attracted recent interest (Al-Majed et aL, 2003, Appenroth et 
al., 1997, Atessahin et al., 2005, De Martinis and Bianchi, 2001, Shimeda et al., 
2005). Importantly, the natural product antioxidants may eliminate ROS in kidneys, 
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without affecting the anticancer efficacy of cisplatin. These antioxidants could have 
potential chemotherapeutic applications. 
1.6. Polyphenols 
Polyphenols are a major class of plant secondary metabolites, characterized by 
the presence of more than one phenol unit or building block per molecule. 
Polyphenols are generally divided into hydrolyzable tannins and phenylpropanoids, 
such as lignins, flavonoids, and condensed tannins. 
Polyphenols are the most abundant antioxidants in our diet and are widespread 
constituents of fruits, vegetables, chocolate and beverages, such as tea, coffee and 
wine (D'Archivio et al.，2007). However, the healthy effects of polyphenols have 
come to the attention only in the last years. As antioxidants, polyphenols may protect 
cells against oxidative stress damage, therefore, limit the risk of various degenerative 
diseases associated to oxidative stress. Experimental studies strongly support the role 
of polyphenols in the prevention of cancer, cardiovascular disease, osteoporosis, 
diabetes mellitus and neurodegenerative disease (Scalbert et al., 2005). For example, 
genistein, a phenolic compound, has been found to have protective effect against 
cisplatin-induced renal injury in mice (Sung et al., 2008). 
1.7. Anthocyanins 
Anthocyanins are common plant pigments, which is a group belongs to 
flavonoids. Anthocyanins are water-soluble pigments, responsible for most of the red, 
blue and purple colors of fruits, vegetables, flowers and other plant tissues or 
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products (Mazza et al., 2004). Anthocyanins are widely distributed in the human diet, 
which can be found in red wine, certain varieties of cereals and certain vegetables 
(cabbage, beans, onions, radishes), especially in fruit. Food contents are generally 
proportional to color intensity and reach values up to 2-4 g/kg fresh wt in 
blackcurrants or blackberries. The contents of anthocyanins increase as the fruit 
ripens. Anthocyanins are found mainly in the fruit skin, except for some red fruits 
(cherries and strawberries) in which they also occur in the flesh (Es-Safi et al.，2002). 
Anthocyanins have been reported to have positive effects in the treatment of 
various diseases (Cao et al., 2001) and are prescribed as medicines in many countries. 
The anthocyanin-health properties are due to their particular chemical structure. The 
electron deficiency makes anthocyanins very reactive towards ROS. Anthocyanins 
are included in the list of natural compounds known to work as powerful 
antioxidants. 
1.8. Rose 
Roses are one of the most important groups of ornamental plants and have been 
referred to as the queen of flowers. Rose is a perennial flower of the genus Rosa, 
within the family Rosaceae, which contains over 100 species and appears in a variety 
of colors. More than 24,000 cultivars of roses have been registered (Ogata et al., 
2005). Rose pigments are composed mainly of the structurally simple anthocyanidin 
3, 5-O-diglucoside. Rose is not only a well-known ornamental plant but also a 
common traditional Chinese medicinal herb. The flowers of rose are traditionally 
used for treating catamenia disorder, trauma, blood disorders, hemostasia and 
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controlling pain and diarrhoea (Cai et al., 2005). 
Plants are known to contain different types of secondary metabolites, such as 
phenolic acids, flavonoids (e.g., flavonols, anthocyanins), fragrant components and 
hydrolysable and condensed tannins (Mikanagi et al., 2000). Different species ofrose 
have been reported to have antioxidant activity. For example, Rosa rugosa flower 
extracts were reported to contain garlic acid and its derivatives, which increased the 
activities of antioxidant enzymes and reduced lipid peroxidation fNg et al., 2005, Ng 
et al., 2004). Rosa persica flower extracts contained polyphenolic antioxidant 
constituents with strong free radical scavenging activity, while Rosa damascena 
flower extracts demonstrated antioxidant and antibacterial activities (Cai et aL, 
2005). 
1.9. Cyanidin 
Cyanidin is considered as one of the widest spread anthocyanin in the plant 
kingdom and largely distributed in the human diet (Galvano et al., 2007), including 
crops, beans, fruits, vegetables and red wines, suggesting that we daily ingest 
significant amounts of these compounds from plant-based diets. The flowers, 
especially red and purple ones, also contain big amounts of cyanidin and its 
glycosides, for example rose. 
Cyanidin and its glycosides were known to act as powerful antioxidants, who 
demonstrated an activity 4 times stronger than that of Trolox (Rice-Evans et al., 
1995), which is a water-soluble derivative of vitamin E. In addition, Youdim et al. 
investigated that preincubation of anthocyanin extracted from blueberry skin, 
12 
containing cyanidin-glycosides and cyanidin, could afford significant resistance to 
induce oxidative stress in red blood cells (Youdim et aL, 2000). Biological models 
have been also used by Tsuda et al. in order to examine the antioxidative activity 
exerted by cyanidin. The results showed cyanidin demonstrated a stronger activity in 
liposomes and rabbit erythrocyte membranes (Galvano et aL, 2004). 
Cyanidin also has anticancer properties, demonstrated by the proliferation rate 
of HepG2, human liver cancer cells was significantly inhibited after the treatment of 
the raspberry extract, in which cyanidin is the major active component (Liu et al., 
2002). Cyanidin ability to inhibit the growth of human tumor cells in vitro has 
recently been monitored in the human vulva carcinoma cell line A431, where 
cyanidin shutting off the downstream signaling cascades and inhibited the epidermal 
growth-factor receptor (Meiers et al., 2001). However, the protective effect of 
cyanidin against cisplatin-induced nephrotoxicity has not yet been investigated. 
1.10. Objectives of this project 
Our previous studies have showed that rose aqueous extract and cyanidin could 
be potential candidates to prevent cisplatin-induced nephrotoxicity. Therefore, in the 
present study, human proximal tubular epithelial (HK-2) cells would be used as an 
experiment model to investigate the protective effects of rose extract and cyanidin 
against cisplatin-induced proximal tubular cell damage and examine the mechanism 
involved in this action. 
Firstly, we would study the cell apoptosis in HK-2 cells induced by cisplatin by 
various apoptosis detection assays, such as flow cytometric analysis and 
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TUNEL-DAPI co-staining assay. We would also examine the activation of caspases 
by Western blotting and caspase activity assay. At the same time, the protective 
effects of rose extract and cyanidin against cisplatin-induced apoptosis would also be 
investigated. 
Secondly, examination of how Bcl-2 family proteins regulate caspase activation 
would be carried out. We should examine the changes of the expression levels of 
Bcl-2 family proteins (including Bcl-2, Bcl-XL, Bax and so on) in apoptotic cells 
induced by cisplatin and the effects of cyanidin. The involvement of the p53 
signaling pathway in cisplatin-induced apoptosis would also be investigated to study 
the crosstalk between these two apoptotic pathways. In considering whether 
mitochondria play a role in cisplatin-induced apoptosis in HK-2 cells, we would 
measure the change of mitochondrial membrane potential (MMP) by flow cytometric 
analysis. The protective effects of cyanidin on mitochondrial function would also be 
examined. 
Thirdly, we would study the relationship between ROS generation, DNA 
damage and apoptosis in HK-2 cells to examine whether ROS acts as the upstream 
signal to induce cell apoptosis. 
Finally, activation of MAPK and AKT pathways would be investigated to 
explore the mechanisms involved in cisplatin-induced apoptosis. The specific 
inhibitors of MAPKs and AKT would be used to fmd out the major pathways that 
modulate the cisplatin-induced apoptotic cell death. 
Taken together, this project aims to find some supports for cyanidin against 
cisplatin-induced nephrotoxicity and explore the possible mechanisms. 
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Chapter Two: Materials and Methods 
2.1. Materials 
Cisplatin, propidium iodide (PI), thiazolyl blue tetrazolium bromide (MTT), 
solid JC-1, 4',6-Diamidino-2-phenyindole (DAPI), 2',7'-dichlorofluorescein diacetate 
(DCF-DA), was purchased from Sigma. Cyanidin was purchased from Polyphenols. 
Rose extract was extracted in our lab from Rosa rugosa. All of the antibodies used in 
this study were purchased from Cell Signaling Technology (Beverly, MA), and 
bicinchoninic acid kit for protein concentration measurement was purchased from 
Sigma. Reagent kit for single cell gel electrophoresis assay (Comet Assay) was 
purchased from Trevigen. Cytotoxicity detection kit (LDH) was obtained from Roche 
Molecular Biochemicals. The mitochondrial dye mitotracker red (CM-H2R0s) was 
obtained from Molecular Probes. The water used for all experiments was ultrapure, 
supplied by a Milli-Q water purification system from Millipore. 
2.2. Cell culture 
HK-2, a proximal tubular cell (PTC) line derived from normal human kidney, 
and HeLa, a human cervix adenocarcinoma cell line were both obtained from 
American Type Culture Collection (ATCC, Manassas, VA) and grown in Dulbecco's 
modified Eagle's medium (DMEM), supplemented with 10 % fetal bovine serum 
(FBS), 100 units/ml penicillin and 50 units/ml streptomycin in a humidified 
incubator with 5 % C02 atmosphere at 37 °C. Reagents for cell cultures were 
purchased from GIBCO. The number of both living and dead cells was counted 
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under microscopy with staining by trypan blue solution. 
2.3. Drug treatment 
HK-2 cells were seeded at 60000 cells/ml. The cells were treated with different 
concentrations of cisplatin for the appropriate times. Pretreatment with cyanidin was 
done for 3 hours before the application of cisplatin. 
2.4. MTT assay 
Cell viability was determined by measuring the ability of cells to reduce MTT 
substrate to a purple formazan dye (Chen and Wong, 2009). HK-2 cells were seeded 
in 96-well tissue culture microplates at 6 x 104 cells/well for 24 h，and then the cells 
were incubated with different treatments for different periods of time. After 
incubation, 20 ^il/well of MTT solution (5 mg/ml in phosphate buffered saline) was 
added and incubated for 4 h. The medium was aspirated and the formazan salt 
formed was dissolved by 150 ^il/well o fDMSO. The color intensity of the formazan 
solution, which reflects the cell growth condition, was measured at 570 nm by using 
a microplate spectrophotometer (SpectroAmax™ 250). 
2.5. Lactate dehydrogenase (LDH) assay 
LDH assay is used for quantification of cytotoxicity. Cytoplasmic LDH released 
from damaged cells was used as a marker for cell membrane integrity (Chen and 
Wong, 2009). The treated cells were precipitated by centrifugation at 1500 x g for 10 
min at room temperature. 100 ml of aliquots of supernatants were transferred into 
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new wells in 96-well plate. Cytotoxicity detection kit (Roche, Germany) was used to 
determine LDH activity. The amount of intracellular LDH released was used to 
evaluate the damage of plasma membrane. According to the manufacturer's 
guidelines, the cells exposed to 1 % Triton X-100 were used as high control (100 % 
lysis), while cells in culture medium as low control. 
2.6. TUNEL-DAPI co-staining assay 
Apoptotic DNA fragmentation was detected by TUNEL-DAPI co-staining assay 
as described previously (Chen and Wong, 2009). Briefly, treated HK-2 cells were 
fixed with 3.7 % formaldehyde for 1 h at room temperature. After washed by PBS, 
cells were permeabilized with 0.1 % Triton X-100 in PBS for 2 min. And then, the 
cells were incubated with 50 ^l/well TUNEL reaction mixture containing nucleotide 
mixture and terminal deoxynucleotidyl transferase (TdT) for 1 h and 1 jig/ml of 
DAPI for 15 min at 37 °C respectively. Stained cells were then washed with PBS and 
observed under fluorescence microscope fNikon Eclipse 80i). 
2.7. Flow cytometric analysis 
The cell cycle distribution was analyzed by flow cytometry as previously 
described (Chen and Wong, 2009). HK-2 cells were trypsinized after treatment, 
washed with PBS and fixed in 75 % ethanol overnight at -20°C. The fixed cells were 
stained with PI (1.21 mg/ml Tris, 700 U/ml RNase, 50.1 pg/ml PI, pH 8.0) for 4 h in 
darkness. The stained cells were analyzed with FC-500 flow cytometer (Beckman 
Coulter, Miami, FL). Cell cycle distribution was analyzed using MultiCycle software 
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(Phoenix Flow Systems, San Diego, CA). DNA histogram was represented by the 
proportion of cells in G0/G1，S, G2/M phases. Apoptotic cells with hypodiploid DNA 
content were measured by quantifying the sub-Gl peak in the cell cycle pattern. For 
each experiment, 10,000 events were recorded. 
2.8. Determination of caspase-3 activity 
Caspase-3 is the early marker of apoptosis. Its activity was determined by using 
a fluorometric method. Treated HK-2 cells were harvested and collect as cell pellets, 
which were suspended in cell lysis buffer and incubated on ice for 1 h. After 
centrifugation at 11,000 x g for 15 min, supernatants were collected and immediately 
measured for protein concentration and caspase-3 activity. Briefly, cell lysates were 
placed in 96-well plates and then specific caspase-3 substrates (Ac-DEVD-AMC) 
and HEPES reaction buffer (50 m M Hepes pH 7.4，0.1 % CHAPS, 10 % Glycerol, 2 
m M EDTA, 5 m M DTT) were added. Plates were incubated at 37 °C for 1 h and 
caspase activity was determined by fluorescence intensity with the excitation 
wavelength at 380 nm and emission wavelengths at 440 nm, respectively. 
2.9. Measurement of ROS generation 
The relative levels of ROS were determined by a DCF-DA fluorometric assay. 
HK-2 cells were seeded in 96-well microplates at 6 x 104 cells/well for 24 h, and then 
the cells were incubated with different treatments for different periods of time. After 
incubation, treated HK-2 cells were incubated with 10 |iM DCFH-DA at 37°C for 15 
min. The medium was aspirated and cells were washed by PBS twice. Before 
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measurement, 100 ^il PBS was added into each well and immediately measured for 
ROS level. The generation o fROS was determined by fluorescence intensity with the 
excitation and emission wavelengths set at 485 and 525 nm, respectively. Relative 
DCF fluorescence intensity of treated cells was expressed as percentage of control. 
2.10. Evaluation of mitochondrial membrane potential 
HK-2 cells in 6-well plates were trypsinized after treatment, washed with PBS 
and resuspended in 0.8 ml of PBS buffer containing 10 ^g/ml of JC-1. After 
incubation for 20 min at 37。C, cells were immediately centrifuged to remove the 
supernatant. Cell pellets were suspended in PBS and then analyzed by flow 
cytometry. The cells that lost A ^ m were represented by the percentage of the green 
fluorescence from JC-1 monomers. 
2.11. Single Cell Gel Electrophoresis (Comet Assay) 
Single-cell gel electrophoresis for detection of DNA damage was performed by 
the Comet assay reagent kit purchased from Trevigen according to the 
manufacturer's instructions. Briefly, treated HK-2 cells were harvested by 
centrifugation at 1500 rpm for 5 min and resuspended in ice-cold PBS at cell density 
of 1 x 105 cells/ml. The cell suspension was mixed with melted LM agarose at a ratio 
of 1:10 (v/v) and 75 jal of the mixture was immediately pipetted onto the slide 
(CometSlide™). After incubation on ice for 40 min, the slide was immersed in 
prechilled lysis solution and refrigerated for 40 min, followed by immersing in 
freshly prepared alkaline solution (300 mM NaOH, 1 mM EDTA, pH >13) for 40 
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min on ice in darkness. After DNA unwinding, the slide was subjected to alkaline 
solution for electrophoresis in a Savant ps 250 system set at 300 mA and 1 volt/cm 
for 40 min. After electrophoresis, the slide was rinsed with distilled H2O, fixed and 
dehydrated in 70 % ethanol for 5 min and air-dried overnight. In the second day, 
DNA was stained with SYBR Green I (Trevigen) and observed under fluorescence 
microscope ONTikon, Eclipse 80i), Fifty cells per slide were selected randomly and 
their olive tail moments were determined by using an image analysis system (Komet 
3.1, Kinetics Imaging Ltd., Liverpool) linked to a CCD camera. 
2.12. Western blot analysis 
Treated HK-2 cells were harvested and collected as cell pellets, which were 
lysed with RIPA lysis buffer (50 mM Tris-Cl pH 7.4, 150 m M NaCl, 1 % NP-40, 0.5 
% sodium deoxycholate, 0.1 % SDS) on ice for 1 h. After centrifugation at 14,000 x 
g for 15 min, supernatants were collected and measured for protein concentration by 
using bicinchoninic acid assay (Sigma) according to the manufacturer's instructions. 
The samples were mixed with sample buffer, boiled for 5 mins and store at -80°C 
until use. 
SDS-PAGE was done in 30 % acrylamide gels loading equal amount of proteins 
per lane (40 p,g of protein per lane). After electrophoresis, separated proteins were 
transferred to nitrocellulose membrane at 100 V for 1.5 h. The membrane then 
blocked with 5 % non-fat milk in TBST buffer (50 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 0.02 % Tween-20) for 1 h at room temperature. After then, the membranes 
were incubated with primary antibodies at 1:1000 dilutions ovemight at 4°C in 5 % 
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non-fat milk, followed by incubated with secondary antibodies conjugated with 
horseradish peroxidase at 1:2000 dilutions for 1 h at room temperature. Protein bands 
were detected on X-ray film using an enhanced chemiluminescence system (Kodak). 
P_actin was used to assess the presence of comparable amount of proteins in each 
lane. 
2.13. Statistical analysis 
Experiments were carried out at least in triplicate and results were expressed as 
mean 士 SD. Differences between two groups were analyzed by two-tailed Student's t 
test while those between three or more groups were analyzed by one-way analysis of 
variance (ANOVA). Difference with P < 0.05 (*) or P < 0.01 (**) was considered 
statistically significant. 
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Chapter Three: Results 
3.1 Cyanidin attenuates cisplatin-induced cytotoxicity in HK-2 cells 
3.1.1. Cytotoxicity induces by cisplatin in HK-2 cells 
Firstly, the cytotoxic effects of cisplatin in HK-2 cell were examined by using 
MTT reduction assay. As shown in Fig. 3.1, cisplatin decreased cell viability of HK-2 
cells in a dose- and time-dependent manner. For instance, cells treated with 8 p,g/ml 
cisplatin for 24 h showed reduced cell viability by approximately 50 % relative to 
control cells. To further confirm the growth inhibition of cisplatin in HK-2 cells, 
LDH assay was used to investigate the plasma membrane leakage. Similar the results 
of MTT assay, cisplatin induced dose- and time-dependent LDH leakage from cells 
into cytosol (Fig. 3.2). 
Consistent with these results, microscopic examinations revealed that cisplatin 
effectively induced time- and dose-dependent morphological changes, such as cell 
shrinkage and the appearance of apoptotic bodies (Fig. 3.3). 
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Fig. 3.1 Cisplatin induced cytotoxicity in HK-2 cell. Cell viability was determined by 
MTT assay. (A) Cisplatin induced cytotoxicity in HK-2 cells in dose-dependent 
manner. The cells were treated with or without 1-16 p,g/ml cisplatin for 24 h, cell 
viability was examined as described in Section 2. (B) Cisplatin induced cytotoxicity 
in HK-2 cells in time-dependent manner. The cells were treated with 8 p,g/ml 
cisplatin for the appropriate times. * P < 0.05, ** P < 0.01 vs untreated controls. 
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Fig. 3.2 Cisplatin induced plasma membrane leakage in HK-2 cell. Plasma 
membrane leakage was determined by LDH assay. (A) Cisplatin induced plasma 
membrane leakage in HK-2 cells in dose-dependent manner. The cells were treated 
with or without 1-16 p,g/ml cisplatin for 24 h, LDH release was examined as 
described in Section 2. (B) Cisplatin induced plasma membrane leakage in HK-2 
cells in time-dependent manner. The cells were treated with 8 ^ig/ml cisplatin for the 
appropriate times. * P < 0.05，** P < 0.01 vs untreated controls. 
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Fig. 3.3 Cisplatin induced morphological changes in HK-2 cell. Morphology change 
of HK-2 cells under different treatments was observed under microscopy 
(magnification, 200x). The arrow indicated morphology changes, including cell 
shrinkage and apoptotic bodies. (A) The cells were treated with or without 2-16 
fig/ml cisplatin for 24 h. (B) The cells were treated with 8 ^ig/ml cisplatin for the 
appropriate times. 
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3.1.2. Rose extract attenuates cisplatin-induced cytotoxicity and LDH leakage 
The cytotoxic effect induced by cisplatin was significantly attenuated by 
co-treatment with rose aqueous extract in a dose-dependent manner (Fig. 3.4A). For 
instance, at concentration of 160 [xg/ml, rose extract increased the cell viability to 
82.3 %，which shows no difference with that of control. This result was further 
confirmed by LDH assay. Similar the results of MTT assay, rose aqueous extract 
dose-dependently attenuated cisplatin-induced LDH leakage (Fig. 3.4B). In addition, 
rose extract prevented cisplatin-induced morphological changes (Fig. 3.6). 
3.1.3. Cyanidin attenuates cisplatin-induced cytotoxicity and LDH leakage 
Cyanidin is an essential active component of rose extract. The cytotoxic effect 
induced by cisplatin was significantly attenuated by co-treatment with cyanidin in a 
dose-dependent manner (Fig. 3.5A). At concentrations of20 and 40 pg/ml, cyanidin 
increased the cell viability to 73.6 % and 85.6 %, which were significantly higher 
than that of cisplatin treatment group (64 %). Cells treated with 40 ^tg/ml cyanidin 
alone showed no difference in cell viability from that of control cells. 
Similar with the results of co-treatment with rose extract, cyanidin significantly 
decreased the LDH release level from 115 % to 98 % (Fig. 3.5B) and prevented 
cisplatin-induced morphological changes (Fig. 3.6). 
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Fig. 3.4 Rose extract attenuated cisplatin-induced cytotoxicity and plasma membrane 
leakage in HK-2 cell. Cells were pretreated with or without rose extract (40-160 
^ig/ml) for 3 h and then cultured in the presence or absence of 8 pg/ml cisplatin for 
24 h. (A) Cell viability was determined by MTT assay. (B) Plasma membrane 
leakage was determined by LDH assay. All data were obtained from three 
independent experiments and presented as the means 士 SD. Bars with different 
characters are statistically different at P < 0.05 level. 27 
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Fig. 3.5 Cyanidin attenuated cisplatin-induced cytotoxicity and plasma membrane 
leakage in HK-2 cell. Cells were pretreated with or without cyanidin (10~40 p,g/ml) 
for 3 h and then cultured in the presence or absence of 8 jag/ml cisplatin for 24 h. (A) 
Cell viability was determined by MTT assay. (B) Plasma membrane leakage was 
determined by LDH assay. All data were obtained from three independent 
experiments and presented as the means 士 SD. Bars with different characters are 
statistically different at P < 0.05 level. 
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Fig. 3.6 Cyanidin and rose extract prevented cisplatin-induced morphological 
changes in HK-2 cell. Morphology change of HK-2 cells under different treatments 
was observed under microscopy (magnification, 200x). (A) Cells were pretreated 
with or without 160 ^ig/ml rose extract for 3 h and then cultured in the presence or 
absence of 8 p,g/ml cisplatin for 24 h. (B) Cells were pretreated with or without 40 
fig/ml cyanidin for 3 h and then cultured in the presence or absence of 8 ^ig/ml 
cisplatin for 24 h. 
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3.1.4. Cyanidin did not affect cisplatin-induced cytotoxicity in HeLa cell 
HeLa is a human cervix adenocarcinoma cell line. To examine whether cyanidin 
would inhibit the anticancer activity of cisplatin or not, the cell viability change of 
HeLa cell was observed. From Fig. 3.7，the cytotoxic effect induced by cisplatin 
showed no difference from that of co-treatment with cyanidin. Cells treated with 40 
M'g/ml cyanidin alone showed no difference in cell viability from that of control cells. 
The results indicated that cyanidin did not affect cisplatin-induced cytotoxicity in 
HeLa cell. 
a a 
^ 1 0 0 - _ _ 
80- • • 
__ii_ll 
Cisplatin (pg/ml) - 8 8 8 8 -
Cyanidin(pg/ml) - - 10 20 40 40 
Fig. 3.7 Cyanidin did not attenuate cisplatin-induced cytotoxicity in HeLa cell. Cell 
viability was determined by MTT assay. Cells were pretreated with or without 40 
p,g/ml cyanidin for 3 h and then cultured in the presence or absence of 8 p,g/ml 
cisplatin for 24 h. All data were obtained from three independent experiments and 
presented as the means 士 SD. Bars with different characters are statistically different 
a tP<0 .05 level. 
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3.2. Cyanidin rescues HK-2 cells from cisplatin-induced apoptosis 
3.2.1. Cisplatin induces cell apoptosis in HK-2 cells 
Cell cycle distribution was monitored by flow cytometric analysis. Cells at 
different phases in cell cycle have differenent DNA content, which can be displayed 
in a flow cytometric diagram. The patterns give information on the cell cycle 
distribution and therefore to be employed to confirm apoptosis. We first examined 
the cisplatin-induced apoptosis in HK-2 cells by using flow cytometric analysis. Data 
in Fig. 3.7 showed that cisplatin induced a dose-dependent increase in sub-Gl cell 
population, which reflected the occurrence of cell apoptosis. 
3.2.2. Rose extract rescues HK-2 cells from cisplatin-induced apoptosis 
With co-treatment of rose extract, the sub-Gl cell population induced by 
cisplatin was significantly decreased in a dose-dependent manner (Fig. 3.8). 
Moreover, cells treated with 160 p,g/ml rose extract alone showed no difference in 
sub-Gl population from that of control cells. 
Cisplatin-induced HK-2 cell apoptosis was further confirmed by DNA 
fragmentation as examined by TUNEL-DAPI co-staining assay (Fig. 3.9). Protection 
of rose extract was also examined by TUNEL-DAPI assay. After exposure to 8 p,g/ml 
cisplatin, HK-2 cells exhibited typical apoptotic morphology, such as formation of 
apoptotic bodies, chromatin condensation and DNA fragmentation, as indicated by 
the arrows. Co-treatment with rose extract effectively prevented these 
cisplatin-induced morphological changes. Meanwhile, the control cells and rose 
extarct-treated cells showed normal nuclei shape. The number of TUNEL-positive 
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nuclei in cisplatin-treated HK-2 cells was significantly increased, by comparing with 
the control group. However, in the presence of rose extract, the number of 
TUNEL-positive nuclei was significantly reduced in cisplatin-treated HK-2 cells, and 
returned to the level of control cells. 
3.2.3. Cyanidin rescues HK-2 cells from cisplatin-induced apoptosis 
By co-treatment with cyanidin, the sub-Gl peak induced by cisplatin was 
significantly decreased in a dose-dependent manner (Fig. 3.10). Cells treated with 40 
|xg/ml cyaniding alone showed no difference in sub-Gl population from that of 
control cells. 
The protection of cyanidin was also examined by DNA fragmentation using 
TUNEL-DAPI co-staining assay. After the exposure to 8 jag/ml cisplatin, HK-2 cells 
exhibited typical apoptotic bodies which evidenced as chromatin condensation and 
condensed nuclear fragment, as indicated by the arrows in Fig. 3.11 (first panel). 
Co-treatment with cyanidin prevented these cisplatin-induced morphological changes 
while control cells and cyanidin-treated cells showed normal nuclei shape. Protective 
effect in HK-2 cells against cisplatin-induced apoptosis was further confirmed by 
detecting DNA fragmentation using the TUNEL assay. As shown in Fig. 3.11 (middle 
panel), in cisplatin-treated HK-2 cells, the number of TUNEL-positive nuclei was 
significantly increased, compared to normal cells. In the presence of cyanidin, the 
number of TUNEL-positive nuclei was significantly reduced in cisplatin-treated 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8 pg/ml Cisplatin 
Control 160 pg/ml Rose extract - 160 pg/ml Rose extract 
• • • • 
• • • • • • • • 
Fig. 3.10 Rose extract rescued HK-2 cells from cisplatin-induced DNA 
fragmentation. Cells were pretreated with or without 160 p,g/ml rose extract for 3 h 
and then cultured in the presence or absence of 8 p,g/ml cisplatin for 24 h, as 
described in Section 2. White arrows indicate condensed nuclei. Top: Evaluation of 
apoptosis in HK-2 cells was examined by DAPI staining (magnification, 200x). 
Middle: DNA fragmentation was detected by TUNEL assay (magnification, 200x). 
TUNEL-positive nuclei due to DNA fragmentation appear as green color. Bottom: 
Merged images of DAPI staining and TUNEL for the same area. The images shown 
































































































































































































































































































































































































































































































































































































































































































































































































































































































8 Mg/ml Cisplatin 
Control 40 pg/ml Cyanidin - 40 pg/ml Cyanidin 
侧 曲 幽 國 睡 
•
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Fig. 3.12 Cyanidin rescued HK-2 cells from cisplatin-induced DNA fragmentation. 
Cells were pretreated with or without 40 p,g/ml cyanidin for 3 h and then cultured in 
the presence or absence of 8 p,g/ml cisplatin for 24 h, as described in Section 2. 
White arrows indicate condensed nuclei. Top: Evaluation of apoptosis in HK-2 cells 
was examined by DAPI staining (magnification, 200x). Middle: DNA fragmentation 
was detected by TUNEL assay (magnification, 200x). TUNEL-positive nuclei due to 
DNA fragmentation appear as green color. Bottom: Merged images of DAPI staining 
and TUNEL for the same area. The images shown here are representative of three 
independent experiments with similar results. 
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3.3. Cyanidin suppresses cisplatin-induced activation of caspase and cleavage of 
PARP 
3.3.1. Cisplatin induces activation of caspase-3. 
To investigate the underlying mechanisms in cisplatin-induced apoptosis, we 
examined whether caspase-3 was involved in this process. Caspase-3 was considered 
to be an important effector that can be cleaved and activated during apoptosis. In Fig. 
3.12A and B，exposure of HK-2 cells to cisplatin resulted in dose- and 
time-dependent increase in the caspase-3 activity. 
3.3.2. Rose extract suppresses cisplatin-induced activation of caspase-3 
Co-treatment with rose extract dose-dependently reduced the cisplatin-induced 
caspase-3 activation, as demonstrated by reduction of caspase-3 activity from 843 % 
(cisplatin group) to 234 % and 257 % by co-treatment with 160 and 80 ^ig/ml rose 
extract (Fig. 3.13). The treatment of rose extract alone showed no difference of 
caspase-3 activity compared with the control. 
3.3.3. Cyanidin suppresses cisplatin-induced activation of caspase-3 
Co-treatment with cyanidin dose-dependently reduced the cisplatin-induced 
caspase-3 activation, as demonstrated by reduction of caspase-3 activity from 892 % 
(cisplatin group) to 228 % with 40 ^ig/ml cyanidin, while 357 % with 20 p,g/ml 
cyanidin (Fig. 3.14). The treatment of cyanidin alone showed no difference of 
caspase-3 activity compared with the control. 
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Fig. 3.13 Cisplatin induced activation of caspase-3 in HK-2 cells. Caspase activity 
was measured with whole cell extracts by a fluorometric method as described in 
Section 2. Ac-DEVD-AMC was used as the substrates for caspase-3. (A) Cisplatin 
induced the activation of caspase-3 in HK-2 cells in dose-dependent manner. Cells 
were treated with or without 1-8 ^ig/ml cisplatin for 24 h. (B) The time course of 
activation of caspase-3 in HK-2 cells induced by cisplatin. Cells were treated with 8 
p,g/ml cisplatin for various periods of time. Data are presented as means 士 SD from 
three independent experiments, each performed in duplicate. Significant difference 
between treatment and control groups is indicated at P < 0.05 (*) and P < 0.01 (**). 
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Fig. 3.14 Rose extract suppressed cisplatin-induced activation of caspase-3 in HK-2 
cells, Caspase activity was measured with whole cell extracts by a fluorometric 
method as described in Section 2. Ac-DEVD-AMC was used as the substrates for 
caspase-3. Cells were pretreated with or without rose extract (40-160 ^ig/ml) for 3 h 
and then cultured in the presence or absence of 8 ^g/ml cisplatin for 24 h. Data are 
presented as means 土 SD from three independent experiments, each performed in 
duplicate. Bars with different characters are statistically different at P < 0.05 level. 
1000 j b~ j 
c? . f 800 _ 
1 i o 600 j • c 
I P 400 • j L 丄 
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Cisplatin (Mg/ml) - 8 8 8 8 -
Cyanidin(pg/ml) - - 10 20 40 40 
Fig. 3.15 Cyanidin suppressed cisplatin-induced activation of caspase-3 in HK-2 
cells. Cells were pretreated with or without cyanidin (10^-0 p,g/ml) for 3 h and then 
cultured in the presence or absence of 8 p,g/ml cisplatin for 24 h. Data are presented 
as means 士 SD from three independent experiments, each performed in duplicate. 
Bars with different characters are statistically different at P < 0.05 level. 
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3.3.4. Rose extract suppresses cisplatin-induced caspase activation and PARP 
cleavage 
Activation of caspase-3 was further confirmed by Western blot analysis. As 
shown in Fig. 3.15, cisplatin-induced activation of caspase-3 in HK-2 cells after 24-h 
treatment, as evidenced by decrease in the level of pro-caspase-3 (35 kDa) and 
increase in the level of cleaved caspase-3 (19 and 17 kDa), Co-treatment with rose 
extract markedly attenuated the activation of caspase-3. 
Caspase is a family of cysteine proteases that play essential roles in apoptosis. 
Apoptosis can be triggered by either extrinsic or intrinsic pathways. To examine the 
caspase-dependent apoptosis pathway, more caspases were also be investigated by 
Western blot analysis. From the results, exposure of HK-2 cells to cisplatin resulted 
in caspase-7, caspase-9 and caspase-8 activation, evidenced by the cleavage of 
pro-caspase protein (Fig, 3.15), indicating both the intrinsic and extrinsic apoptosis 
pathways were involved in cisplatin-induced apoptosis. Co-treatment with rose 
extract markedly attenuated the activation of caspase-7, caspase-9 and caspase-8. 
PARP serves as a marker of apoptosis, which previously demonstrated as a 
DNA repair enzyme that is downstream of caspase-3 in the apoptotic pathways. After 
24-h treatment with cisplatin, HK-2 cell showed cleavage of PARP at 85 kDa and 
reduced level of total PARP (116 kDa), and recovered by co-treatment with rose 
extract (Fig. 3.15). 
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Fig. 3.16 Rose extract blocked cisplatin-induced activation of caspase and cleavage 
ofPARP in HK-2 cells. Cells were pretreated with or without 160 p,g/ml rose extract 
for 3 h and then incubated with 8 ^,g/ml cisplatin for 24 h. Cell lysates were 
subjected to Western blot analysis as described in Section 2. The expression levels of 
caspase-3, caspase-7, caspase-8, caspase-9 and PARP were shown. Equal protein 
loading was confirmed by analysis of p_actin in the protein extracts. This experiment 
was repeated twice with similar results. 
Cisplatin (8 pg/ml) - + + - Cisplatin (8 pg/ml) - + + -
Cyanidin (40 pg/ml) - - + + Cyanidin (40 pg/ml) - - + + 
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Fig. 3.17 Cyanidin blocked cisplatin-induced activation of caspase and cleavage of 
PARP in HK-2 cells. Cells were pretreated with or without 40 ^ig/ml cyanidin for 3 h 
and then incubated with 8 p,g/ml cisplatin for 24 h. Equal protein loading was 
confirmed by analysis of p-actin in the protein extracts. This experiment was 
repeated twice with similar results. 
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3.3.5. Cyanidin suppresses cisplatin-induced caspase activation and PARP cleavage 
Similar to rose extract, we also examined the protective effects of cyanidin 
against cisplatin-induced caspase activation and PARP cleavage. Activation of 
caspase-3 was confirmed by Western blot analysis. In Fig. 3.16, cisplatin-induced 
activation of caspase-3 in HK-2 cells after 24-h treatment, while co-treatment with 
cyanidin markedly attenuated the activation of caspase-3. 
For PARP and the other caspase proteins, after 24-h treatment with cisplatin, 
HK-2 cells showed cleavage of PARP, which was recovered by co-treatment with 
一 cyanidin (Fig. 3.16). Moreover, exposure of HK-2 cells to cisplatin resulted in 
caspase-7, caspase-9 and caspase-8 activation (Fig. 3.16). However, co-treatment 
with cyanidin markedly attenuated the activation of caspase-7, caspase-9 and 
caspase-8. 
3.4. Cyanidin rescues HK-2 cells from cisplatin-induced mitochondrial 
dysfuntion by regulating the expression of Bcl-2 family proteins 
3.4.1. Cyanidin prevents cisplatin-induced loss of mitochondrial membrane potential 
(AWm) 
Mitochondria play an important role in the regulation of apoptosis, by 
integrating the apoptotic signals originating from both the extrinsic and intrinsic 
apoptosis pathways (van Gurp et aL, 2003). Loss of A ^ m is associated with the 
activation of caspases and then initiates apoptotic cascades. Therefore, we studied 
whether cisplatin-induced apoptosis occurred through losing mitochondrial potential. 
HK-2 cells were treated with different concentrations of cisplatin for 24 hr and A^m 
was detected by flow cytometry using JC-1 as a molecular probe. JC-1 is a cationic 
dye that exhibits potential-dependent accumulation in mitochondria. With the loss of 
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A^m, the fluorescence of JC-1 dye turns red to green. Therefore, the cell with the 
loss o f A ^ m shows increase of green fluorescence. As shown in Fig. 3.17A, cisplatin 
induced dose-dependent loss of A^Fm in HK-2 cells. However, co-treatment with 
cyanidin significantly prevented the disruption of A ^ m in dose-dependent manner 
(Fig.3.17B). 
3.4.2. Cyanidin regulates the expression of Bcl-2 family proteins to prevent 
cisplatin-induced mitochondrial dysfunction 
Bcl-2 family members have been described as the central regulator of 
mitochondrial permeability and caspase activation (Cory and Adams, 2002). 
Therefore, the effects of cisplatin on the expression levels of pro-survival and 
pro-apoptotic Bcl-2 family proteins in HK-2 cells were examined by western blotting. 
As shown in Fig. 3.18, cisplatin significantly increased the expression levels of Bax, 
while the expression level of Bad slightly increased. In addition, the expression of 
Bcl-XL, Bcl-2, Mcl-1 and Bim was not affected by cisplatin treatment. Therefore, the 
expression ratio of both Bcl-2/Bax and Bcl-XL/Bad were decreased. The results in Fig. 
3.18 demonstrated that cisplatin induced the truncation ofBid in HK-2 cells, which is 
consistent with the activation of caspase-8 in response to cisplatin treatment. With 
the co-treatment of cyanidin, the expression level of Bad and Bax decreased, 
compared to that of cisplatin single-treatment, while the expression level of Bid also 
back to control level. These results indicate that mitochondrial-mediated apoptosis in 
HK-2 cells triggered by cisplatin is associated with down-regulation of expression 
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Fig. 3.19 Cyanidin rescued cisplatin-induced cell apoptosis by regulating Bcl-2 
family proteins in HK-2 cells. Cells were pretreated with or without 40 p,g/ml 
cyanidin for 3 h and then incubated with 8 p,g/ml cisplatin for 24 h. The expression 
levels of Bcl-2, Bax, Bcl-XL, Bad, Mcl-1, Bid and Bim were analyzed by Western 
blot. Equal protein loading was confirmed by analysis of p-actin in the protein 
extracts. This experiment was repeated twice with similar results. 
3.5. Cyanidin reduces cisplatin-induced apoptosis by suppressing the activation 
of p53 
Our previous results showed that cisplatin treatment up-regulated the expression 
of some p53-inducible genes, such as Bax and Bad (Fig. 3.18)，suggesting that p53 
pathway could be involved in cisplatin-induced apoptosis. To examine whether p53 
is activated by cisplatin, we examined the expression level of total p53 and 
phosphorylation in HK-2 cells treated with cisplatin for 24 h. As shown in Fig. 3.19, 
cisplatin treatment resulted an increase of total and phosphorylated p53 at Ser 392, 
Ser 15 and Ser 9. However, phosphorylation at residues of Ser 6 and Ser 20 were not 
detected in cisplatin treated cells. These results indicated that Ser 392, Ser 15 and Ser 
9 were the major phosphorylation site of p53 induced by cisplatin. For total p53 and 
phosphorylated p53 with increase expression level, co-treatment with cyanidin 
returned protein level to control or lower than that of control. Protein level of a DNA 
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damage marker p - H 2 A was also up-regulated in HK-2 cells treated with cisplatin, 
while co-treatment with cyanidin reduced the increase of expression level of p - H 2 A . 
Taken together, these results indicate that activation of p53 pathway is required for 
cisplatin-induced apoptosis and cyanidin can reduce cisplatin-induced apoptosis by 
regulating p53 induction. 
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Fig. 3.20 Cyanidin reduced cisplatin-induced apoptosis by regulating p53 induction 
in HK-2 cells. Western blot analysis of expression levels of p53, p21 and p27, and 
phosphorylation of p53 and histone H2A in HK-2 cells. Cells were pretreated with or 
without 40 p,g/ml cyanidin for 3 h and then incubated with 8 p,g/ml cisplatin for 24 h. 
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3.6. Cyanidin inhibits ROS-mediated DNA damage in HK-2 cells 
3.6.1. Cyanidin prevents cisplatin-induced DNA damage 
Cisplatin is well-known as DNA-binding reagent, which could defect DNA or 
arrest DNA synthesis (Pabla and Dong, 2008). So we investigated the induction of 
DNA damage by cisplatin using Comet assay, which provides a measurement ofboth 
single- and double-strand breaks in DNA. We observed DNA damage induced by 
cisplatin in HK-2 cells. As shown in Figure 3.20, a significant elevation of DNA 
strand breaks (DSBs) in HK-2 cells was detectable in cells exposed to 8 ^tg/ml 
cisplatin for 24 h. However, co-treatment with 40 jig/ml cyanidin significantly 
prevented this damage, as evidenced by significant decrease in olive tail moments 
from 28.6 to 9.9. The change of head and tail DNA showed the similar results (Fig. 
3.21). 
3.6.2. Cyanidin inhibits cisplatin-induced accumulation ofROS 
ROS plays an important role in the induction of apoptosis by various 
chemotherapeutic agents (Pelicano et aL, 2004). To further explore the biochemical 
basis contributing to protective effects of cyanidin in HK-2 cell, cisplatin-induced 
ROS generation and free radical scavenging ability of cyanidin were examined in 
HK-2 cells. Intracellular ROS was detected by fluorescein-labeled dye, DCFH-DA. 
HK-2 cells were treated with different concentrations of cisplatin for 2 h and 
measured for fluorescence intensity. Cells treated for 2 ^ig/ml cisplatin resulted a 
significantly increase of intracellular ROS as shown by increased fluorescence 
intensity (Fig. 3.22A), with which ROS increased to 124 % of control cells. 
Co-treatment with 40 ^ig/ml cyanidin reduced intracellular ROS to 69 % (Fig. 3.22B), 
which was lower than that of control. 
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Fig. 3.21 Cyanidin prevented cisplatin-induced DNA damage in HK-2 cells. (A) 
Protective effects of cyanidin on DNA damage induced by cisplatin. HK-2 cells were 
pretreated with 40 p,g/ml cyanidin for 3 h, followed by incubation with 8 p,g/ml 
cisplatin for 24 h, and then immediately analyzed by Comet assay as described in 
section 2. Arrow indicates cells with damaged DNA. Average olive tail moment is 
listed below each image. (B) The results of olive tail moment change were shown by 
bar chart. Bars with different characters are statistically different at P < 0.05 level. 
All data were obtained from three independent experiments and presented as the 
means 士 SD. 
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Fig. 3.22 Cyanidin prevented cisplatin-induced DNA strand breaks in HK-2 cells. 
HK-2 cells were pretreated with 40 p,g/ml cyanidin for 3 h, followed by incubation 
with 8 |xg/ml cisplatin for 24 h, and then immediately analyzed by Comet assay as 
described in section 2. (A) The results of tail DNA change were shown by bar chart. 
(B) The results of head DNA change were shown by bar chart. Bars with different 
characters are statistically different at P < 0.05 level. All data were obtained from 
three independent experiments and presented as the means 士 SD. 
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Fig. 3.23 Cyanidin inhibited ROS accumulation in HK-2 cells. ROS generation was 
determined by measuring the fluorescence intensity of an oxidation-sensitive 
fluorescein DCFH-DA as described in Section 2. Intracellular levels of ROS in 
treated cells are expressed as percentages of control cells. (A) Cisplatin induced ROS 
g e n e m t i 0 n i n H K ' 2 c e l l s . C e l l s _ e treated with or without 1-16 ^ g/ml cisplatin for 
2 h. (B) Cyanidin suppressed cisplatin-induced accumulation o fROS in HK-2 cells. 
C d l s w e r e P r e t r e a t e d w i t h o r without cyanidin ( 10^0 ^g/ml) for 3 h and then 
cultured in the presence or absence of 2 ^g/ml cisplatin for 2 h. All data are 
expressed as means 士 SD oftriplicates. Bars with different characters are statistically 
different at P < 0.05 level. 
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3.7. Cyanidin suppresses cisplatin-induced apoptosis by activation of AKT, JNK 
and ERK 
3.7.1. Cisplatin activates ERK artd AKT pathways 
MAPK signaling pathway plays an important role in cell death or cell survival. 
We determined whether the MAPKs were activated in cisplatin-treated HK-2 cells by 
Western blot analysis using specific antibodies binding to the phosphorylated forms 
of the kinases. Fig. 3.23A and B showed that exposed the cells to cisplatin in 
different time and different concentrations, phosphorylated forms of both JNK and 
ERK were activated in dose- and time-dependent manner, but no effect on level of 
total kinases. Activation of p38 by cisplatin was observed as early as 1 h after 
cisplatin treatment, which peaked at approximately 2-4 h and declined thereafter, and 
the total p38 had no change in expression level with cisplatin treatment in HK-2 
cells. 
The serine/threonine protein kinase PKB/AKT is a key mediator of signal 
transduction processes during apoptosis (Lawlor and Alessi, 2001). In Fig. 3.23, 
exposure of the cells to cisplatin resulted in activation of AKT, including total protein 
and phosphorylated forms. The expression level of total and phosphorylated AKT 
decreased in both time- and dose-dependent manner. 
3.7.2. Cyanidin suppresses cisplatin-induced activation of MAPKs and AKT 
pathways 
To explore the role of MAPK kinases and AKT in the mechanism of protection 
of cyanidin, we examined the effects of cyanidin on cisplatin-mediated MAPK and 
AKT signaling pathways. From the results of Western blotting analysis, we observed 
that pretreatment of HK-2 cells with cyanidin rescued cisplatin-induced expression 
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oftotal and phosphorylated AKT (Fig. 3.24). At the same time, pretreatment ofHK-2 
cells with cyanidin also supressed cisplatin-induced phosphorylation of JNK and 
ERK (Fig. 3.24). 
丄 7.3. AKT and ERK Inhibitors attenuates cisplatin-induced apoptosis in HK-2 cells 
To determine whether MAPKs or AKT are important for cisplatin-induced 
apoptosis, we first used specific inhibitors of MAPKs and AKT to examine 
cisplatin-induced cytotoxicity in HK-2 cells. We pretreated HK-2 cells with 
LY294002 (AKT inhibitor), SB202190 (p38 inhibitor), U0126 (ERK inhibitor) and 
SP600125 (JNK inhibitor) to measure cell viability by MTT assay. The results 
showed U0126 significantly prevented cisplatin-induced cytotoxicity while 
LY294002 significantly decreased cell viability. In the contrast, pretreatment of cells 
with SB202190 and SP600125 showed no significant effects against 
cisplatin-induced cytotoxicity (Fig. 3.25). The observation of cell morphology 
change also elucidated similar results (Fig. 3.26). 
In addition, we found that LY294002 partially induced the cisplatin-induced 
apoptosis while U0126 significantly prevented the cisplatin-induced apoptosis as 
detected by flow cytometry (Figure 3.27). Consistent with these results, pretreatment 
with LY294002 and U0126 effectively blocked the cisplatin-induced caspase-3 
activation and PARP cleavage (Fig 3.28).These results indicated the important roles 
of AKT and ERK pathways in cisplatin-induced apoptosis, and cyanidin protected 
HK-2 cells from cisplatin-induced apoptosis partly through suppression of AKT and 
ERK. 
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Fig. 3.24 Cisplatin induced activation of MAPKs and AKT in HK-2 cells. (A) The 
time course of activation of MAPKs and AKT in HK-2 cells induced by cisplatin. 
Cells were treated with 8 ^tg/ml cisplatin and harvested at various times. Cell lysates 
were subjected to Western blot analysis, as described in Section 2. Protein levels of 
phosphorylated AKT, total AKT, phosphorylated JNK, total JNK, phosphorylated 
p38, total p38, phosphorylated ERK and total ERK were determined. (B) Activation 
of MAPKs and AKT in HK-2 cells induced by cisplatin in dose-dependent manner. 
Cells were treated with or without 4-16 ^ig/ml cisplatin for 24 h and subjected to 
Western blot analysis. P-Actin was used as an equal protein control. This experiment 
was repeated twice with similar results. 
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Fig. 3.25 Cyanidin blocked cisplatin-induced activation of MAPKs and AKT in 
HK-2 cells. Cells were pretreated with or without 40 ^ig/ml cyanidin for 3 h and then 
incubated with 8 ^ig/ml cisplatin for 24 h and subjected to Western blot analysis. 
Protein levels of phosphorylated AKT, total AKT, phosphorylated JNK, total JNK, 
phosphorylated p38, total p38, phosphorylated ERK and total ERK were determined. 
P-Actin was used as an equal protein control. This experiment was repeated twice 
with similar results. 
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Fig. 3.26 AKT and ERK inhibitors attenuated cisplatin-induced cytotoxicity in HK-2 
cells. Effect o fAKT and MAPK inhibitors on cell viability ofcisplatin-treated HK-2 
cells. The cells were pretreated with specific inhibitors o fAKT (LY294002 20 ^M) 
and MAPKs (JNK inhibitor SP600125 20 ^iM, p38 inhibitor SB202190 20 jLiM, ERK 
inhibitor U0126 10 jaM) for 1 h and then incubated in the presence or absence of 8 
pg/ml cisplatin for 24 h. Cell viability was determined by MTT assay as described in 
Section 2. All data are expressed as means 土 SD of triplicates. Bars with different 
characters are statistically different at P < 0.05 level. 
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Fig. 3.27 AKT and ERK inhibitors prevented cisplatin-induced morphological 
changes in HK-2 cell. Morphology change of HK-2 cells under different treatments 
was observed under microscopy (magnification, 200x). (A) Cells were pretreated 
with or without 20 ^M LY294002 for 1 h and then cultured in the presence or 
absence of 8 jag/ml cisplatin for 24 h. (B) Cells were pretreated with or without 10 
^M U0126 for 1 h and then cultured in the presence or absence of 8 pg/ml cisplatin 
for 24 h. 
57 
( A ) 8 pg/ml Cisplatin 
Control LY294002 - LY294002 
Sub G1 : 5.89% ~ ~ Sub G1 : 4.30% Sub G1 : 32.38% ~ ~ Sub G1 : 43.98% 
；! G1 : 63.97% G1 : 75.98% G1 :48.73% G1 : 39.56% 
S ： 14.48% S:8.92% S:9 .93% S : 11.09% 
^ G2 : 15.66% G2 : 10.80% G2 : 8.96% G2 : 5.37% 
1 L i 1. L 丄 … y^Li. 
C 
= Control U0126 - U0126 
• ~ ~ Sub G1 : 3.60% ~ ~ SubG1 :4.21% ~~|Sub G1 : 31.45% ~ ~ Sub G1 : 8.54% 
G1 : 67.52% G1 : 89.47% G1 : 45.91% G1 : 65.75% 
S ： 12.36% S : 8.92% S : 10.82% S : 12.64% 
G2 : 16.52% G2 : 10.80% G2 : 11.82% G2 : 13.07% 
^^| ^i_j^hi^ i t^^ Bfa^k _ji^ L^ddrik 
DNA content 
( B ) ^ j 1 
1 101 a I _ 4 4 ^ 
⑴ o J j i i i _ _ • _ _ • _ _ • _ _ • _ _ m J 
Cisplatin (8 pg/ml) - + + + - -
LY294002 - - + - + -
U0126 - - - + - + 
Fig. 3.28 AKT and ERK inhibitors influenced HK-2 cells from cisplatin-induced 
apoptosis. Quatitative analysis of apoptotic cell death induced by cisplatin in HK-2 
cells by flow cytometric analysis. Cells were pretreated with or without AKT 
inhibitor (LY294002 20 ^iM) or ERK inhibitor (U0126 10 ^M) for 1 h and then 
incubated in the presence or absence of 8 ^ig/ml cisplatin for 24 h. (A) Results shown 
by flow cytometric diagram. (B) The results of sub-Gl population change were 
shown by bar chart. Bars with different characters are statistically different at P < 
0.05 level. All data were obtained from three independent experiments and presented 
as the means 士 SD. 
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Fig. 3.29 AKT and ERK inhibitors suppressed cisplatin-induced caspase-3 activation 
and PARP cleavage in HK-2 cells. Treated cells were subjected to Western blot 
analysis. (A) Cells were pretreated with or without 20 ^iM LY294002 for 1 h and 
then cultured in the presence or absence of 8 昭/ml cisplatin for 24 h. Protein levels 
ofPARP, caspase-3, phosphorylated AKT, total AKT, phosphorylated ERK and total 
ERK were determined. (B) Cells were pretreated with or without 10 jiM U0126 for 1 
h and then cultured in the presence or absence of 8 ^ig/ml cisplatin for 24 h. Protein 
levels of PARP, caspase-3, phosphorylated ERK and total ERK were determined. 
P-Actin was used as an equal protein control. This experiment was repeated twice 
with similar results, p-actin was used as an equal protein control. This experiment 
was repeated twice with similar results. 
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Chapter Four: Discussion 
Cisplatin-induced nephrotoxicity is the major limitation of its usage during 
chemotherapy. In the present study, we demonstrated that cyanidin protects HK-2 
proximal tubular cells against cisplatin-induced cell apoptosis and the possible 
mechanisms. Our results showed that cisplatin inhibited the growth of HK-2 cells, 
and induced cell apoptosis, as evidenced by accumulation of sub-Gl population, 
chromatin condensation, DNA fragmentation and damage, activation of caspase, 
cleavage of PARP and mitochondrial dysfunction. Apoptosis of HK-2 cells was also 
associated with increased intercellular ROS levels, regulating p53 induction, as well 
as activation of AKT and p38 MAPKs. These cisplatin-induced changes were 
significantly rescued by co-treatment with cyanidin, mainly due to attenuation of 
oxidative stress, reduction of p53 induction and modulation of the ERK and AKT 
signaling pathways. 
4.1. Cell model and cisplatin treatment 
HK-2 is an immortalized proximal tubular cell (PTC) line derived from normal 
human kidney, which differed from cancer cells. HK-2 cells retain functional 
characteristics of in vivo proximal tubules and primary PTC cultures. The origin of 
HK-2 cells, human kidney, represents a major potential advantage over currently 
available animal or human embryonic derived cell lines, which is a powerful tool for 
the study of mechanisms of cell injury and repair (Ryan et al., 1994). 
Cisplatin is widely used for chemotherapy and is potent for various types of 
solid tumors. For clinical usage, cisplatin is administered intravenously. 
Administration time is typically 30 minutes to 2 hours. The rate of administration is 
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typically 1 mg/minute infusion. Treatment dose of cisplatin varies for different 
cancers. Combination with other approved chemotherapeutic agents is 20 mg/m2 IV 
daily for 5 days per cycle. While worked as single agent, cisplatin should be 
administered at a dose o f l 00 mg/m2 IV per cycle once every four weeks. 
In this project, the treatment concentration of cisplatin was according to the cell 
viability change of cisplatin in HK-2 cells. Accumulation of cisplatin in HK-2 cells 
resulted in a dose-dependent growth inhibition, which IC50 values at 8.6 ^ig/ml. So 
the concentration of 8 ^ig/ml of cisplatin was used for further experiments. 
4.2. Cisplatin nephrotoxicity and its renoprevention 
Cisplatin nephrotoxicity is major limiting factor in the use of cisplatin in 
chemotherapy. Cisplatin induces a frequent adverse effect in renal tubules and leads 
to acute renal failure. Nephrotoxicity was reported in the initial clinical trials of 
cisplatin chemotherapy (Hill and Speer, 1982). The prevalence of cisplatin 
nephrotoxicity is high and about one-third of patient suffer from it during treatment 
(Luke et al., 1992). Clinically, cisplatin-induced nephrotoxicity is often seen after 10 
days of cisplatin administration and is manifested as lower glomerular filtration rate, 
higher serum creatinine and reduced serum magnesium and potassium levels (Arany 
and Safirstein, 2003, Gomez Campdera et aL, 1986, Gonzales-Vitale et al., 1977). 
Exposure of tubular cells to cisplatin activates complex signaling pathways which 
lead to tubular cell injury and death. 
Cisplatin-induced nephrotoxicity is recognized as a very complex multifactorial 
process. The pathophysiological basis of cisplatin nephrotoxicity has been studied for 
the last three decades. However, only recently research directed towards some 
understandings ofthe cellular and molecular mechanism. Primary targets ofcisplatin 
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in kidney are proximal tubules, where it promotes cellular damage, and induces 
nephrotoxicity through oxidative stress, DNA damage, cell apoptosis, and 
inflammation (Ramesh and Reeves, 2002, Winston and Safirstein, 1985). 
During the investigation of cisplatin-induced nephrotoxicity, a plethora of 
pharmacologic, molecular, and genetic approaches have been identified for 
renoprotection (Pabla and Dong, 2008). The approaches can be classified on the basis 
of their primary targets, including cisplatin uptake, metabolism and bioactivation, 
cell death pathways, cell cycle regulators, p53, MAPKs, oxidative stress, 
inflammation and so on. The renoprotective agents against cisplatin nephrotoxicity 
could be single regulator or regulated multiple targets. 
4.3. Rose extract prevents cisplatin-induced apoptosis in HK-2 cells 
Rose is known as a common traditional Chinese medicinal herb. The flowers of 
rose are traditionally used for treating catamenia disorder, trauma, blood disorders, 
hemostasia and controlling pain and diarrhoea (Cai et al., 2005). Different species of 
rose have been reported to have antioxidant activity. For example, Rosa rugosa 
flower extracts were reported to contain gallic acid and its derivatives, which 
increased the activities of antioxidant enzymes and reduced lipid peroxidation fNg et 
al.，2005, Ng et al., 2004). Rosa persica flower extracts contained polyphenolic 
antioxidant constituents with strong free radical scavenging activity, while Rosa 
damascena flower extracts demonstrated antioxidant and antibacterial activities (Cai 
et al., 2005). As oxidative stress is an important factor in cisplatin nephrotoxicity, the 
possible role of rose against cisplatin-induced apoptosis in HK-2 cells would be a 
valuable topic. 
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4.3.1. Rose extract prevents cisplatin-induced apoptosis in HK-2 cells 
Apoptosis is the process of programmed cell death that occurs in multicellular 
organisms. It leads to cell morphology changes and death. These changes include 
loss of cell membrane asymmetry and attachment, blebbing, cell shrinkage, nuclear 
and chromosomal DNA fragmentation and chromatin condensation. Cisplatin 
induces apoptosis or necrosis in renal tubule cells. And apoptosis the predominant 
mode of cell death induced by cisplatin in proximal tubule cells (Jiang et al., 2006). 
In B M K cells, cisplatin induced apoptosis in p53-deflcient renal cells via the intrinsic 
mitochondrial pathway (Jiang et al., 2009). Except for in vitro study, apoptosis also 
occurred in animal models during cisplatin-induced renal dysfunction (Liu and 
Baliga, 2003，Megyesi et aL, 1998, Ramesh and Reeves, 2003). 
In the present study, we showed that cisplatin suppressed cell viability o f HK-2 
cells as evaluated by MTT assay. Co-treatment of rose extract reduced these 
cytotoxic effects of cisplatin. With PI flow cytometric analysis, cisplatin induced 
HK-2 cell apoptosis as evidenced by increased sub-Gl population. Rose extract 
attenuated the accumulation of sub-Gl population induced by cisplatin in HK-2 cells. 
Under fluorescence microscope, HK-2 cells treated with cisplatin exhibited cell 
shrinkage, shape irregularity and formation of apoptotic body when stained by DAPI. 
During apoptosis, DNA fragments in the nucleus and DNA nicks can be examined by 
TUNEL assay. Our results demonstrated that cisplatin induced an increase of DNA 
fragmentation in HK-2 cells and the morphological features of apoptosis were 
prevented by co-treatment with rose extract. Taken together, rose extract prevented 
cisplatin-induced cytotoxicity in HK-2 cells mainly through inhibition of apoptosis. 
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4.3.2. Rose extract inhibits cisplatin-induced caspase activation and PARP cleavage 
Caspases are cysteine proteases and activated by cleaved after aspartic acid 
residues (Bonegio and Lieberthal, 2002). A group of caspases functions as a part of 
the apoptotic cascade, and involves in two central mechanisms, the extrinsic ^N[agata, 
1997) and intrinsic pathways (Li et al., 1997). In previous research, cisplatin-induced 
injury to renal tubular epithelial cells through enhancing activation of caspase-3 and 
the initiator caspase, caspase-9 (Kaushal et aL, 1998). Cisplatin also caused 
mitochondrial release of cytochrome c and caspase-3 activation (Kojima et aL, 1998). 
In agreement with the previous studies, our data showed that cisplatin induced 
apoptosis of HK-2 cells as evidenced by multiple caspase activation and PARP 
cleavage (Fig. 3.15). Caspase-3 activation is a key hallmark of apoptosis in 
mammalian cells (Putt et al., 2006). Our results showed that cisplatin caused 
activation of caspase-3 in HK-2 cells, and hence triggered apoptosis. Activation of 
caspase-3 leads to the cleavage of PARP. PARP is a DNA repair protein that can be 
activated by DNA strand cleavages (Schreiber et al., 2006). The cleavage of PARP 
serves as a marker of cell apoptosis. 
Apoptosis induced by cisplatin involved several pathways, including the 
extrinsic pathway mediated by death receptors, the intrinsic pathway centered on 
mitochondria and the endoplasmic reticulum (ER)-stress pathway (Danial and 
Korsmeyer, 2004, Green and Reed, 1998, Pabla and Dong, 2008, Strasser et al., 
2000). In the extrinsic pathway, binding of the death receptors by ligands at the 
plasma membrane leads to the activation of caspase-8, which farther induce 
apoptosis (Strasser et al., 2000). Major death receptors include Fas, tumor-necrosis 
factor-a (TNF-a) receptor (TNFR) 1 and 2. For example, an upregulation of Fas and 
Fas ligand by cisplatin, which was associated with apoptosis, was shown in cultured 
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human proximal tubular cells (Razzaque et al., 1999). In TNFRl-deficient cells and 
mice, Tsuruya et aL demonstrated the amelioration of cisplatin-induced tubular cell 
apoptosis and renal failure, suggesting the involvement of TNFR1 signaling in 
cisplatin nephrotoxicity (Tsuruya et al., 2003). O f note, TNF-a and its receptors may 
induce renal injury primarily by mounting a disastrous inflammatory response rather 
than by directly activating the extrinsic pathway of apoptosis (Razzaque et al., 1999). 
The intrinsic or mitochondrial pathway has emerged as the major apoptotic pathway 
in cisplatin-induced nephrotoxicity. In the intrinsic pathway, cellular stress leads to 
the activation of Bcl-2 family proteins, which forms porous defects on the outer 
membrane of mitochondria, resulting in the release of apoptogenic factors from the 
organelles and leads to the activation of caspase-9, which also induces apoptosis 
(Danial and Korsmeyer, 2004, Green and Reed, 1998, Strasser et al., 2000). Bax 
accumulation in mitochondria and cytochrome c release in cultured kidney cells 
suggested the involvement of the intrinsic pathway of apoptosis in cisplatin-induced 
renal injury (Lee et al., 2001). In renal epithelial cells, Lee et al. and Park et al. 
provided the first evidence for Bax activation during cisplatin treatment, 
accompanied by mitochondrial release of cytochrome c, activation of caspase-9 and 
apoptosis (Lee et aL, 2001, Park et al., 2002). 
Cleavage of caspase-8 and caspase-9 demonstrated the activation of both 
extrinsic and intrinsic apoptosis pathways. The intrinsic pathway was also found to 
crosstalk with the extrinsic pathway through the truncation of Bid, which transfered 
the apoptotic signal from the cell surface to mitochondria. Our study indicated that 
rose extract treatment blocked the activation of caspase family, including caspase-3, 
caspase-7, caspase-8 and caspase-9, and cleavage of PARP caused by cisplatin in 
HK-2 cells. Taken together, our results suggest that the anti-apoptotic effects of rose 
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extract involve the suppression of the caspase-mediated pathway, including both 
extrinsic and intrinsic apoptosis pathways. 
4.4. Cyanidin prevents cisplatin-induced apoptosis in HK-2 cells 
4.4.1. Cyartidin will not affect cisplatin-induced cell death in HeLa cells 
Cisplatin is a widely used chemotherapeutic drug and considered as one of the 
most remarkable successes in "the war on cancer" (Pabla and Dong, 2008). 
Searching for a compound which can inhibit cisplatin-induced nephrotoxicity 
without affecting the anticancer effect of cisplatin becomes the most interesting 
insight. So whether cyanidin would affect cisplatin-induced cell death in cancer cell 
lines were examined. 
Cisplatin is used to treat ovarian, testicular, head and neck and uterine cervical 
carcinoma. HeLa, human cervix adenocarcinoma cell line, was used to examine 
whether cyanidin would affect the anticancer effect of cisplatin or not. The results 
showed cyanidin will not affect cisplatin-induced cell death in HeLa cells, evidenced 
by no significantly change of cell viability with cotreatment of cisplatin and 
cyanidin. 
4.4.2. Cyanidin prevents cisplatin-induced apoptosis by inhibiting caspase activation 
and PARP cleavage in HK-2 cells 
Cyanidin is the major components of anthocyanins in rose. In previous results, 
rose demonstrated the protective effects on cisplatin-induced apoptosis, including 
suppression of cytotoxicity, prevention of plasma membrane leakage, decreasing 
sub-Gl population, rescuing DNA fragmantion, inhibition of caspase activation and 
PARP cleavage. Interesting, cyanidin showed similar protective effects as that of rose, 
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while stronger effects on some of the aspects, for example, stronger prevention 
effects on cisplatin-induced plasma membrane leakage. These results indicated that 
similar as rose extract, cyanidin prevented cisplatin-induced apoptosis by inhibiting 
caspase activation and PARP cleavage in HK-2 cells, which suggested that cyanidin 
was worth to be further investigated for the mechanism involved in this protection 
effect against cisplatin-induced cell apoptosis in HK-2 cells. 
4.4.3. Cyanidin prevents the cisplatin-induced loss of mitochondrial membrane 
potential by regulating Bcl-2 proteins in HK-2 cells 
In many instances, mitochondrial membranes permeabilization is an important 
step of apoptotic cell demise (Kroemer et al., 2007). In the present study, HK-2 cells 
showed depletion of A ^ m as early as 1 ^ig/ml cisplatin treatment and gradually 
increased with the increase of the concentration of cisplatin. 
The mitochondrial apoptosis pathway is regulated by Bcl-2 family proteins 
which classify into two groups, proapoptotic proteins, such as Bax, Bad and Bid, and 
antiapoptotic proteins, such as Bcl-2 and Bcl-xL. Bak is associated with outer 
memebrane, whereas Bax resides in the cytosol, under normal circumstances. The 
expression of Bax or Bak is required for mitochondrial membranes permeabilization 
in cell apoptosis induction (Wei et al., 2001). Bcl-2 and Bcl-xL bind to the outer 
membrane of mitochondria in healthy cells. However, with the stimulation of 
apoptotic signals, Bax translocates to the mitochondria membrane and forms 
membrane integrated homo-oligomers with Bak. The oligomers permeabilize the 
outer mitochondrial membrane and trigger the loss of ATm (Cory and Adams, 2002). 
Preivous evidences suggested that cisplatin treatment leaded to the decrease of the 
antiapoptotic proteins including Bcl-2, Bcl-xL and Mcl-1 (Jiang et al., 2006, Yang et 
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al., 2007), whereas the proapoptotic proteins such as Bax and Bak remained 
unchanged or even increased in cultured tubular cells. In vivo, the ratio of Bax/Bcl-2 
is elevated during cisplatin nephrotoxicity (Sheikh-Hamad et al., 2004, Wei et al., 
2007a). In addition, PUMA-a (p53-upregulated modulator of apoptosis) was induced 
in a p53-dependent fashion during cisplatin nephrotoxicity (Jiang et al., 2006). From 
the previous studies, many anticancer drugs induce mitochondria-mediated apoptosis 
in cancer and normal cells through down-regulation of Bcl-2/Bcl-XL and/or 
up-regulation of Bax/Bad/Bid. Our results showed that single treatment of cisplatin 
significantly up-regulated Bax and Bad expression. Thus, down-regulation of both 
Bcl-2/Bax and Bcl-xi/Bad expression ratio could be predominant mechanisms by 
which cisplatin induces mitochondria-mediated apoptosis in HK-2 cells. In addition, 
truncation of Bid was also observed in cisplatin-treated HK-2 cells, which might be 
resulted by the activation of the extrinsic apoptosis pathway. Truncated Bid could 
promote the release of mitochondrial proteins into cytoplasm and cause the loss of 
membrane potential. Our study indicated that cyanidin treatment blocked the 
expression of Bax, Bad and Bid, induced by cisplatin in HK-2 cells. Taken together, 
our results suggest that the anti-apoptotic effects of cyanidin involve in the 
suppression of mitochondrial-mediated apoptotic pathways. 
4.4.4. Cyanidin suppresses cisplatin-induced total and phosphorylated p53 activation 
p53 is the well-recognized tumor suppressor protein, which was first suggested 
to involved in cisplatin nephrotoxicity by Cummings and Schnellmann (Cummings 
and Schnellmann, 2002). p53 can directly or indirectly induce cell apoptosis through 
both the extrinsic and intrinsic apoptosis pathways (Hofseth et al., 2004). The 
activation of p53 has been demonstrated to involve in cisplatin-induced 
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nephrotoxicity (Wei et al., 2007b), evidenced by pifithrin-a, a pharmacological 
inhibitor of p53, could partially suppress cisplatin-induced apoptosis in rabbit 
proximal tubular cells (Cummings and Schnellmann, 2002). The role of p53 in 
cisplatin nephrotoxicity is further supported by recently study of in vivo experiments, 
showed p53 activation in renal tubular cells with partially colocalizing with 
apoptosis. 
We have demonstrated that the activation and phosphorylation of p53 were 
required for cisplatin-induced apoptosis in HK-2 cells. As shown in Fig. 3.19, protein 
levels of total p53 and phosphorylated-p53, including Ser 392, Ser 15 and Ser 9, 
were up-regulated by cisplatin treatment. These results suggest that 
mitochondria-mediated apoptosis triggered by cisplatin in HK-2 cells is p53 
dependent. Meanwhile, phosphorylation of H2A in cisplatin treated HK-2 cells 
suggests that DNA damage may be the underlying mechanism that activated the p53 
pathway. In the experiment, we also demonstrated that cyanidin inhibited the 
cisplatin-induced activation and phosphorylation of p53 in HK-2 cells. Cyanidin also 
could decrease the expression level of phosphorylated H2A. Therefore we suggested 
that cyanidin decreases cisplatin-induced apoptosis through the regulation of p53 
induction and prevention o fDNA damage in HK-2 cells. 
4.4.5. Cyanidin prevents the cisplatin-induced overproduction of intracellular ROS 
and subsequent DNA damage in HK-2 cells 
Oxidative stress is an imbalance between generation and elimination of ROS, 
which result in overproduction of ROS and induce apoptosis contributing to cell 
death signaling (Czarna and Jarmuszkiewicz, 2006). ROS is an important mediator 
during cell apoptosis induced by cisplatin (Sung et al., 2008). The increment of 
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various reactive oxygen species (ROS) has been demonstrated to occur during 
cisplatin treatment of cultured renal tubular cells, kidney slices, and in vivo in whole 
animals. The central role of ROS accumulation in cisplatin-induced renal failure 
(Davis et al., 2001) is also supported by studies that demonstrate a protective role for 
ROS, such as catalase, vitamin E and glutathione, in cisplatin-mediated 
nephrotoxicity (Appenroth et al., 1997, Lieberthal et aL, 1996, McGinness et al., 
1978, Tsutsumishita et al., 1998) For example, another study conducted in 1999 
showed that oral supplementation of vitamin E could effectively decrease the 
incidence and severity of cisplatin-induced peripheral neurotoxicity and 
nephrotoxicity (Pace et al., 2003). ROS-mediated apoptosis was thought to be 
associated with the dysfunction of the mitochondria, as well as alteration in 
mitochondrial membrane permeability (Boya et al., 2003). The role of mitochondrial 
production of ROS in cisplatin-induced renal injury was further indicated by the 
cytoprotective effects of mitochondria-localized manganese superoxide dismutase 
(Davis et al.,2001). 
We showed that cisplatin significantly induced generation of intracellular ROS 
in HK-2 cells. In addition, rapid disruption of A ^ m after cisplatin treatment was 
detected in HK-2 cells by JC-1 flow cytometric analysis (Fig. 3.17). These results 
suggest that mitochondria play an important role in cisplatin-induced ROS 
generation. Excess production of ROS can damage cell structures such as DNA and 
protein, leading to the generation of a variety of ROS-mediated modified products 
such as DNA strand breaks (DSB) and DNA-protein crosslinks (Lloyd et al., 1997). 
In the cells, DSB is one of the most dangerous types of DNA damage (Modesti and 
Kanaar, 2001). The phosphorylation of histone H2A is a very early cellular event 
induced by DSB. Thus, the phosphorylation of histone H2A was analyzed by western 
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blotting. As shown in Fig. 3.19, a significant increase in the expression level of 
phosphorylated protein was observed in HK-2 cells treated with cisplatin. This result 
suggested that a DNA damage-mediated pathway is involved in cisplatin-induced 
cell apoptosis. Furthermore, our results showed that the overproduction of ROS in 
cisplatin-treated HK-2 cells was attenuated by treatment with cyanidin. Whether 
cyanidin could prevent accumulation of cisplatin needs to be further investigated. 
These findings suggest that cyanidin is capable of scavenging free radicals and 
protecting HK-2 cells against oxidative stress induced by cisplatin. 
4.4.6. Cyanidin suppresses the cisplatin-induced activation of MAPKs and AKT 
pathways in HK-2 cells 
There are several protein kinase pathways that can regulate cell proliferation 
and survival. MAPKs, a family of serine-threonine protein kinases, have been 
implicated to participate in cell proliferation, differentiation and apoptosis. The 
MAPK family includes three kinase members, p38 MAPK, JNK7SAPK and ERK. 
JNK and p38 are activated by oxidative stress, UV irradiation, and osmotic shock 
(Boldt et al., 2002). ERK pathway has been known to plays vital roles in cell growth 
and differentiation, mediating cell survival, but there is growing evidence suggesting 
that the activation of ERKl/2 also involved in cell apoptosis (Jo et al., 2005). 
However, the detailed functions of these MAPK proteins depend on types of cell 
systems and kinds of stimuli. In addition to the MAPKs, another protein kinase AKT 
is able to mediate cell growth via the phosphorylation of a variety of substrates 
including Bad and FOXO transcription factors (Riedl and Shi, 2004). 
ERK, p38, and JNK7SAPK are activated in various experimental models of 
cisplatin-induced nephrotoxicity. In vivo, cisplatin induced the activation of ERK, 
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p38, and JNK/SAPK, which preceded the development of acute renal injury and 
renal failure (Arany et al.，2004). The role for ERK activation in cisplatin-induced 
nephrotoxicity in vivo was recently verified by using U0126 (Jo et al., 2005), which 
is a specific ERK inhibitor. Another example showed that cisplatin treatment 
activated ERK and accumulated in mitochondria during of primary cultures of renal 
tubular cells. Inhibition of ERK with U0126 could ameliorate cisplatin-induced 
mitochondrial dysfunction and apoptosis (Nowak, 2002). Meanwhile, a study ofthe 
treatment with the JNK inhibitor SP600125 showed reduction of renal apoptosis and 
inflammation during cisplatin-induced nephrotoxicity using an in vivo rat model 
(Francescato et al., 2007). 
ERK and JNK usually directly regulate renal tubular cell apoptosis. Instead of 
directly regulating tubular cell death, p38 may regulate TNF-a expression and 
consequent inflammatory response during cisplatin-induced nephrotoxicity (Mishima 
et al., 2006, Ramesh and Reeves, 2005). These evidences demonstrated the role of 
p38 in cisplatin nephrotoxicity by using both in vitro and in vivo models. Specifically, 
SB203580 and SKF-86002, which are pharmacological inhibitors of p38, showed 
renoprotective effects in these models (Mishima et al., 2006, Ramesh and Reeves, 
2005). In TKPTS cells, activation of MAPKs members such as ERK, JNK and p38 
are all activated after the treatment with cisplatin both in vivo and in vitro, however 
only ERK showed contribution to apoptosis (Arany et al., 2004). In LLC-PK1 cells, 
the phosphorylation of AKT was showed a marked induction in both time- and 
dose-dependent manner during the course of cisplatin injury (Kaushal et al., 2001). 
In agreement with these results, our findings demonstrated a mechanistic link 
between the MAPK pathway, AKT, and cispltin-induced cell apoptosis in HK-2 cells. 
Cisplatin treatment triggered the differential activation of JNK, p38 MAPK, ERK, 
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and AKT pathways (Fig. 3.23 and 3.24). Further examination using specific 
inhibitors suggested that JNK and p38 did not play significant roles in regulating cell 
apoptosis induced by cisplatin in HK-2 cells. In support of the pro-apoptosis function 
of ERK and pro-survival function of AKT in the presence of cisplatin, our results 
also indicated that the protective effects of cyanidin in HK-2 cells were mediated by 
suppressing the activation o fERK and AKT pathways. To investigate the relationship 
between ERK and AKT phosphorylation and cisplatin-induced apoptosis, we 
observed the time course of their changes. The results in Fig. 3.23A provided a 
time-dependent change during cisplatin treatment. Exposure of HK-2 cells to 
cisplatin led to a rapid elevation of ERK phosphorylation after 12 h of treatment, 
while a decrease of AKT phosphorylation after 8 h. Furthermore, inhibitors of ERK 
and AKT alone, significantly blocked the cisplatin-induced apoptosis in HK-2 cells, 
indicating that ERK and AKT play critical roles in mediating cisplatin-induced 
growth inhibition. Collectively, our results suggest that modulation of ERK and AKT 
phosphorylation contribute to cisplatin-induced cell apoptosis while cyanidin can 
prevent this kind of damage. 
In summary, the present study demonstrates that cyanidin protects HK-2 
proximal tubular cells against cisplatin-induced cytotoxicity through inhibition of 
cell apoptosis. Treatment with cyanidin attenuates cisplatin-induced caspase 
activation, PARP cleavage, mitochondrial dysfunction, p53 activation, DNA damage 
and activation of ERK and AKT pathways. These effects were partially mediated by 
the antioxidant activity of cyanidin with inhibition of the intracellular ROS 
generation. These results support the potential therapeutic role of cyanidin by 
preventing cisplatin-induced loss of renal tubular cells. 
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Chapter Five: Conclusion 
Cisplatin-induce nephrotoxicity is major limiting factor in the use of cisplatin in 
chemotherapy. Cisplatin treatment leads to subclinical but permanent reduction in 
glomerular filtration rate (Brillet et al., 1994). Exposure of tubular cells to cisplatin 
activates complex signaling pathways which lead to tubular cell injury and death. 
Meanwhile, a robust inflammatory response is stimulated, further exacerbating renal 
tissue damage. These events, together, culminate in renal dysfunction during 
cisplatin-induced nephrotoxicity, triggering acute renal failure. During the 
investigation of cisplatin-induced nephrotoxicity, a plethora of pharmacologic, 
molecular, and genetic approaches have been identified for renoprotection (Pabla and 
Dong, 2008). 
In this project, we studied the protective effects of cyanidin against 
cisplatin-induced apoptosis in HK-2 cells. The results showed that cisplatin inhibited 
the growth of proximal tubular HK-2 cells through induction of apoptosis, as 
evidenced by chromatin condensation and DNA fragmentation. Interestingly, 
cisplatin-induced apoptosis was significantly attenuated by co-incubation with rose 
extract. We also showed that activation of caspase and cleavage of poly (ADP-ribose) 
polymerase (PARP) in cisplatin-treated cells could be effectively blocked by rose 
extract. In addition, in previous experiments, cyanidin demonstrated the stronger 
protective effects than that of rose extract, which indicated cyanidin was worth to be 
further investigated for the mechanism involved in this protection effect against 
cisplatin-induced cell apoptosis in HK-2 cells. 
Moreover, cyanidin prevented the cisplatin-induced loss of mitochondrial 
membrane potential (A^m) by regulating the expression and phosphorylation of 
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Bcl-2 family members, including the pro-survival and pro-apoptotic proteins. HK-2 
cells exposed to cisplatin showed increase in total and phosphorylated p53 on serine 
residues of Ser 392, Ser 15 and Ser 9. However, cyanidin demonstrated the ability to 
suppress cisplatin-induced total and phosphorylated p53 activation. Furthermore, 
cyanidin prevented the cisplatin-induced overproduction of intracellular ROS and 
subsequent DNA damage. Additionally, cisplatin treatment triggered the activation of 
mitogen-activated protein kinases (MAPKs) and AKT pathways，which were also 
effectively suppressed by cyanidin. Inhibitors of ERK (U0126) or AKT (LY294002), 
but not JNK (SP600125) and p38 MAPK (SB203580), significantly suppressed 
cisplatin-induced apoptosis in HK-2 cells. Taken together, our results suggest that 
cyanidin protects HK-2 cells against cisplatin-induced apoptosis through inhibiting 
the ROS generation and modulating the extracellular signal-regulated kinase (ERK) 
and AKT pathways. 
Research during the last few years has gained significant insights into the 
signaling pathways that are responsible for cisplatin nephrotoxicity. Along with the 
mechanistic studies, numerous renoprotective approaches have been documented. 
Identification of the new renoprotective function of cyanidin may have important 
implications for future combinational cancer therapy. By inhibiting ROS generation 
and modulating ERK and AKT pathways, cyaniding may suppress apoptosis in 
normal cells and tissues. This would increase the tolerance of normal tissues to 
therapy-associated toxicity or side effects and, as a result, enhance the therapeutic 
efficacy. Fortunately, cyanidin may not suppress the toxicity in cancer cells and 
reduce the therapeutic effects. The results suggest the potential therapeutic role of 
cyanidin in cancer therapy by preventing cisplatin-induced loss of proximal tubular 
cells. Importantly in further study, the renoprotective effects of cyanidin need to be 
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tested in tumor-bearing animals on cisplatin-mediated chemotherapy in cancers. 
Identification of novel approaches that protect normal tissues including kidneys, 
without limiting therapeutic effects in cancer cells or tumors, would open new 
avenues to enhance cisplatin-based cancer therapy, 
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